IPP Bureau
Sun Pharma Advanced Research posts Q2 FY24 loss at Rs. 86.42 Cr
By IPP Bureau - November 07, 2023
Sun Pharma Advanced Research Company Limited has reported total income of Rs. 29.67 crores during the period ended September 30, 2023
Max Healthcare Institute reports Q2 FY24 consolidated PAT at Rs. 276.68 Cr
By IPP Bureau - November 07, 2023
Max Healthcare Institute has reported total income of Rs. 1408.64 crores during the period ended September 30, 2023
Divis Laboratories posts Q2 FY24 consolidated PAT at Rs. 348 Cr
By IPP Bureau - November 07, 2023
Divi's Laboratories Limited has reported total income of Rs. 1995 crores during the period ended September 30, 2023
Zydus Wellness consolidated Q2 FY24 PAT drops to Rs. 5.9 Cr
By IPP Bureau - November 07, 2023
Zydus Wellness has reported total income of Rs. 444 crores during the period ended September 30, 2023
Metropolis Healthcare reports Q2 FY24 consolidated PAT at Rs. 35.45 Cr
By IPP Bureau - November 06, 2023
Metropolis Healthcare has reported total income of Rs. 309.71 crores during the period ended September 30, 2023
Orchid Pharma consolidated Q2 FY24 net profit up at Rs. 19.80 Cr
By IPP Bureau - November 06, 2023
Orchid Pharma reported total income of Rs. 207.11 crores during the period ended September 30, 2023
Themis Medicare posts Q2 FY24 PAT at Rs. 11.31 Cr
By IPP Bureau - November 06, 2023
The company has reported total income of Rs. 107.22 crores during the period ended September 30, 2023
Poly Medicure posts consolidated Q2 FY24 PAT at Rs. 62.18 Cr
By IPP Bureau - November 06, 2023
Poly Medicure has reported total income of Rs. 351.38 crores during the period ended September 30, 2023
Henkel launches new medical grade wearables device light cure adhesives
By IPP Bureau - November 04, 2023
The newly developed adhesive is available in two different grades. Loctite WT 3001 and Loctite WT 3003 h
Zydus, Guardant Health to promote Guardant360 genomic tests for cancers in India and Nepal
By IPP Bureau - November 04, 2023
The agreement demonstrates a shared commitment to advance precision medicine and improve patient outcomes in the region
Lupin receives tentative approval from USFDA for Selexipag for injection
By IPP Bureau - November 04, 2023
This product will be manufactured at Lupin's Nagpur facility in India
Tatva Chintan Pharma Chem reports Q2 FY24 consolidated PAT at Rs. 7.78 Cr
By IPP Bureau - November 04, 2023
Tatva Chintan Pharma Chem has reported total income of Rs. 97.42 crores during the period ended September 30, 2023
The Prostate Cancer Foundation and Bayer announce Bayer – PCF Darolutamide Challenge Awards
By IPP Bureau - November 03, 2023
In 2022, darolutamide was FDA-approved in combination with docetaxel chemotherapy for adults with metastatic hormone-sensitive prostate cancer
Can-Fite signs agreement with Collaborations Pharmaceuticals to develop anti-cancer drugs using AI
By IPP Bureau - November 03, 2023
This project will aim to develop a next-generation A3 adenosine receptor drug agonists
Lyka Labs posts Q2 FY24 loss at Rs. 48.65 lakhs
By IPP Bureau - November 03, 2023
Lyka Labs has reported total income of Rs. 28.23 crores during the period ended September 30, 2023
